Transcription Factor DP1
-
Subject Areas on Research
- A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
- Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product.
- An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
- Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest.
- Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells.
- Cell cycle: Flies teach an old dogma new tricks.
- Domains of the adenovirus E1A protein required for oncogenic activity are also required for dissociation of E2F transcription factor complexes.
- E2F4-RB and E2F4-p107 complexes suppress gene expression by transforming growth factor beta through E2F binding sites.
- Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
- Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.
- Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function.
- Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
- Isolation and initial characterization of the BRCA2 promoter.
- Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
- Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis.
- Therapeutic applications of transcription factor decoy oligonucleotides.